Johnson & Johnson has stopped development of an eye disease gene therapy after reviewing data from one of its key readouts for 2026.
Source: FierceBiotech
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.